Context-dependent effects of dipeptidyl peptidase 4 inhibitors

Current Opinion in Nephrology and Hypertension

Volumn 26, Issue 2, 2017, Pages 83-90

  Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CXCL12 ; dipeptidyl peptidase 4; gliptins; neuropeptide Y; peptide YY

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; PANCREAS POLYPEPTIDE; STROMAL CELL DERIVED FACTOR 1ALPHA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; PEPTIDE YY; PEPTIDE YY (1-36); STROMAL CELL DERIVED FACTOR 1;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFECT; HEART FAILURE; HUMAN; KIDNEY FAILURE; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; METABOLISM;

ANIMALS; BLOOD PRESSURE; CHEMOKINE CXCL12; DIABETES MELLITUS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDE YY;

EID: 85000432395     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000303     Document Type: Review

References (82)

1. Klemann C, Wagner L, Stephan M, von Horsten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune sys tem. Clin Exp Immunol 2016; 185:1-21.
2. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60:1454-1470.
3. Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121:1868-1877.
4. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24:151-158.
5. Bruce KD, Byrne CD. The metabolic syndrome: common origins of a multi-factorial disorder. Postgrad Med J 2009; 85:614-621.
6. Segura J, Ruilope LM. Treatment of prehypertension in diabetes and metabolic syndrome: what are the pros? Diabetes Care 2009; 32 (Suppl 2):S284-S289.
7. Reynolds K, Wildman RP. Update on the metabolic syndrome: hypertension. Curr Hypertens Rep 2009; 11:150-155.
8. Cheung B. Hypertension as part of the metabolic syndrome. J Hum Hypertens 2008; 22:871-874.
9. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 2005; 128:159-165.
10. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010; 56:728-733.
11. Devin JK, Pretorius M, Nian H, et al. Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl pep-tidase-4 inhibition. Hypertension 2014; 63:951-957.
12. Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009; 54:516-523.
13. White WB, Wilson CA, Bakris GL, et al. Angiotensin-converting enzyme inhibitor use and major cardiovascular outcomes in type 2 diabetes mellitus treated with the dipeptidyl peptidase 4 inhibitor alogliptin. Hypertension 2016; 68:606-613.
14. Berglund MM, Hipskind PA, Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med 2003; 228:217-244.
15. Nyquist-Battie C, Cochran PK, Sands SA, Chronwall BM. Development of neuropeptide Y and tyrosine hydroxylase immunoreactive innervation in postnatal rat heart. Peptides 1994; 15:1461-1469.
16. Warner MR, Senanayake PD, Ferrario CM, Levy MN. Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ Res 1991; 69:455-465.
17. Yang T, Levy MN. Sequence of excitation as a factor in sympathetic-para-sympathetic interactions in the heart. Circ Res 1992; 71:898-905.
18. Sosunov AA, Hassall CJ, Loesch A, et al. Neuropeptide Y-immunoreactive intracardiac neurones, granule-containing cells and nerves associated with ganglia and blood vessels in rat and guinea-pig heart. Cell Tissue Res 1997; 289:445-454.
19. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77:75-197.
20. Haefliger JA, Waeber B, Grouzmann E, et al. Cellular localization, expression and regulation of neuropeptide Y in kidneys of hypertensive rats. Regul Pept 1999; 82:35-43.
21. Anini Y, Fu-Cheng X, Cuber JC, et al. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch 1999; 438:299-306.
22. Fu-Cheng X, Anini Y, Chariot J, et al. Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflugers Arch 1997; 433:571-579.
23. Manning S, Batterham RL. The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on. Annu Rev Physiol 2014; 76:585-608.
24. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg 2006; 16:651-658.
25. Armstrong DN, Ballantyne GH, Adrian TE, et al. Adaptive increase in peptide YY and enteroglucagon after proctocolectomy and pelvic ileal reservoir construction. Dis Colon Rectum 1991; 34:119-125.
26. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90:359-365.
27. MacIntosh CG, Andrews JM, Jones KL, et al. Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility. Am J Clin Nutr 1999; 69:999-1006.
28. Pappas TN, Debas HT, Chang AM, Taylor IL. Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs. Gastroenterology 1986; 91:1386-1389.
29. Teixeira FV, Pera M, Kelly KA. Enhancing release of peptide YY after near-total proctocolectomy: jejunal pouch vs. ileal pouch-distal rectal anastomosis. J Gastrointest Surg 2001; 5:108-112.
30. Esler M, Lambert G, Brunner-La Rocca HP, et al. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiol Scand 2003; 177:275-284.
31. Esler M, Rumantir M, Wiesner G, et al. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 2001; 14:304S-309S.
32. Melanson EL, Astrup A, Donahoo WT. The relationship between dietary fat and fatty acid intake and body weight, diabetes, and the metabolic syndrome. Ann Nutr Metab 2009; 55:229-243.
33. Shaw DI, Hall WL, Williams CM. Metabolic syndrome: what is it and what are the implications? Proc Nutr Soc 2005; 64:349-357.
34. Freire RD, Cardoso MA, Gimeno SGA, et al. Dietary fat is associated with metabolic syndrome in Japanese Brazilians. Diabetes Care 2005; 28:1779-1785.
35. Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 2004; 23:447-456.
36. Michel MC, Beck-Sickinger A, Cox H, et al. XVI International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998; 50:143-150.
37. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85:9-24.
38. Wagner L, Kaestner F, Wolf R, et al. Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation. Neuropeptides 2016; 57:21-34.
39. Jackson EK, Kochanek SJ, Gillespie DG. Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Hypertension 2012; 60:757-764.
40. Zhu X, Gillespie DG, Jackson EK. NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4. Am J Physiol Heart Circ Physiol 2015; 309:H1528-1542.
41. Cheng D, Zhu X, Gillespie DG, Jackson EK. Role of RACK1 in the differential proliferative effects of neuropeptide Y1-36 and peptide YY1-36 in SHR vs. WKY preglomerular vascular smooth muscle cells. Am J Physiol Renal Physiol 2013; 304:F770-780.
42. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005; 45:657-687.
43. Dubey RK, Jackson EK, Rupprecht HD, Sterzel RB. Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr Opin Nephrol Hypertens 1997; 6:88-105.
44. Dubinion JH, Mi Z, Jackson EK. Role of renal sympathetic nerves in regulating renovascular responses to angiotensin II in spontaneously hypertensive rats. J Pharmacol Exp Ther 2006; 317:1330-1336.
45. Dubinion JH, Mi Z, Zhu C, et al. Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction. Hypertension 2006; 47:545-551.
46. Jackson EK, Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 2008; 51:1637-1642.
47. Jackson EK, Zhang M, Liu W, Mi Z. Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther 2007; 323:431-437.
48. Tofovic DS, Bilan VP, Jackson EK. Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clin Exp Pharmacol Physiol 2010; 37:689-691.
49. Jackson EK, Dubinion JH, Mi Z. Effects of dipeptidyl peptidase IV inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol 2008; 35:29-34.
50. Jackson EK, Mi Z, Tofovic SP, Gillespie DG. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Hypertension 2015; 65:238-249.
51. Zhang R, Niu H, Kang X, et al. Long-term administration of neuropeptide Y in the subcutaneous infusion results in cardiac dysfunction and hypertrophy in rats. Cell Physiol Biochem 2015; 37:94-104.
52. Hulting J, Sollevi A, Ullman B, et al. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 1990; 24:102-108.
53. Gouya G, Voithofer P, Neuhold S, et al. Association of nutritional risk index with metabolic biomarkers, appetite-regulatory hormones and inflammatory biomarkers and outcome in patients with chronic heart failure. Int J Clin Pract 2014; 68:1293-1300.
54. Shanks J, Herring N. Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides. Am J Physiol Regul Integr Comp Physiol 2013; 305:R1411-1420.
55. Wang W, Choi BK, Li W, et al. Quantification of intact and truncated stromal cell-derived factor-1a in circulation by immunoaffinity enrichment and tandem mass spectrometry. J Am Soc Mass Spectrom 2014; 25:614-625.
56. Chu P-Y, Zatta A, Kiriazis H, et al. CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ 2011; 4:651-658.
57. Zuk A, Gershenovich M, Ivanova Y, et al. CXCR4 antagonism as a therapeutic approach to prevent acute kidney injury. Am J Physiol Renal Physiol 2014; 307:F783-F797.
58. Yuan A, Lee Y, Choi U, et al. Chemokine receptor Cxcr4 contributes to kidney fibrosis via multiple effectors. Am J Physiol Renal Physiol 2015; 308:F459-472.
59. Schober A, Knarren S, Lietz M, et al. Crucial role of stromal cell-derived factor-1a in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation 2003; 108:2491-2497.
60. Zernecke A, Schober A, Bot I, et al. SDF-1a/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 2005; 96:784-791.
61. Chen HT, Tsou HK, Hsu CJ, et al. Stromal cell-derived factor-1/CXCR4 promotes IL-6 production in human synovial fibroblasts. J Cell Biochem 2011; 112:1219-1227.
62. Jie W, Wang X, Zhang Y, et al. SDF-1a/CXCR4 axis is involved in glucose-potentiated proliferation and chemotaxis in rat vascular smooth muscle cells. Int J Exp Pathol 2010; 91:436-444.
63. Walsh TG, Harper MT, Poole AW. SDF-1a is a novel autocrine activator of platelets operating through its receptor CXCR4. Cell Signal 2015; 27:37-46.
64. Subramanian S, Liu C, Aviv A, et al. Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arterioscler Thromb Vasc Biol 2014; 34:2100-2105.
65. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014; 114:1788-1803.
66. Girardi AC, Fukuda LE, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 2008; 294:F414-F422.
67. Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol 2015; 14:129.
68. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013; 226:305-314.
69. Bostick B, Habibi J, Ma L, et al. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity. Metabolism 2014; 63:1000-1011.
70. Mulvihill EE, Varin EM, Ussher JR, et al. Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice. Diabetes 2016; 65:742-754.
71. Hemmeryckx B, Swinnen M, Gallacher DJ, et al. Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice. Eur J Pharmacol 2014; 723:175-180.
72. Fadini GP, Albiero M, Avogaro A. Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence. Vasc Pharmacol 2015; 73:1-3.
73. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317-1326.
74. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369:1327-1335.
75. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385:2067-2076.
76. Wang K-L, Liu C-J, Chao T-F, et al. Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Int J Cardiol 2014; 177:86-90.
77. Savarese G, Perrone-Filardi P, D'Amore C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. Int J Cardiol 2015; 181:239-244.
78. Chen DY, Wang SH, Mao CT, et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: a nationwide cohort study. Int J Cardiol 2015; 181:200-206.
79. Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, et al. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol 2016; 211:88-95.
80. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardio-vascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:232-242.
81. Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 2016; 374:1145-1154.
82. Oyama J, Murohara T, Kitakaze M, et al. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial. PLoS Med 2016; 13:e1002051.